Evidence map›Paper›PMID 26039810›Full record

ArticleBioanalysis2015

Simultaneous determination of trimethoprim and sulfamethoxazole in dried plasma and urine spots.

Daniel Gonzalez, Chiara Melloni, Brenda B Poindexter, Ram Yogev, Andrew M Atz, Janice E Sullivan, Susan R Mendley, Paula Delmore, Amy Delinsky, Kanecia Zimmerman and 6 more

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Bioanalysis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01431326 completednot on this map

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

TypeobservationalSponsorDaniel BenjaminRan2011 to 2019Enrolled3,520ConditionsAdenovirus, Anesthesia, Anxiety, AnxiolysisArmsThe POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
NCT04278404 recruitingnot on this mapstarted 2020, after this paper: background citation

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

TypeobservationalSponsorDuke UniversityRan2020 to 2026Enrolled5,000ConditionsCoronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, HypertensionArmsThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 1 country.

Daniel Gonzalez
Chiara Melloni2Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Brenda B Poindexter3Department of Pediatrics, Riley Hospital for Children, Indiana University, Indianapolis, IN, USA.
Ram Yogev
Andrew M Atz5Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
Janice E Sullivan6Kosair Charities Pediatric Clinical Research Unit, Department of Pediatrics, University of Louisville, Kosair Children's Hospital, Louisville, KY, USA.
Susan R Mendley7Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.
Paula Delmore8Department of Neonatology, Wesley Medical Center, Wichita, KS, USA.
Amy Delinsky9OpAns, LLC, 4134 S Alston Ave # 101, Durham, NC 27713, USA.
Kanecia Zimmerman2Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Andrew Lewandowski10EMMES Corp., 401 N Washington St # 700, Rockville, MD 20850, USA.
Barrie Harper2Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Kenneth C Lewis9OpAns, LLC, 4134 S Alston Ave # 101, Durham, NC 27713, USA.
Daniel K Benjamin2Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Michael Cohen-Wolkowiez2Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
Best Pharmaceuticals for Children Act--Pediatric Trials Network Administrative Core Committee
Clinical Research Institute · USUnited States Army Research Office · USDuke Medical Center · USEmmes (United States) · USIndiana University – Purdue University Indianapolis · USMedical University of South Carolina · USNorthwestern University · USUniversity of Louisville · USUniversity of Maryland, Baltimore · USUniversity of North Carolina at Chapel Hill · USWesley Medical Center · US

Funding

Duke CTSA (Composite)UL1TR001117 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, LI, JENNIFER S · 2013 to 2017
$41.3M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
Duke CTSA (Composite)KL2TR001115 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, KRAFT, MONICA · 2013 to 2017
$5.1M
Physiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in ChildrenR01HD076676 · NICHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2014 to 2017
$2.6M
Mentorship of early-career pediatricians in quantitiative methods and therapeuticK24HD058735 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2009 to 2018
$1.5M
Clinical Practice Data to Aid Narrow Therapeutic Index Drug ClassificationU01FD004858 · FDA · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2013 to 2014
$497k
FDA HHS 1U01FD004858-01FDA HHS U01 FD004858NCATS NIH HHS KL2 TR001115NCATS NIH HHS UL1 TR001108NCATS NIH HHS UL1 TR001117NCATS NIH HHS UL1TR001117NIAID NIH HHS HHSN272201300017CNIAID NIH HHS HHSN272201300017INIAID NIH HHS HHSN272201500001CNIAID NIH HHS HHSN272201500001GNIAID NIH HHS HHSN272201500006CNICHD NIH HHS 1R01-HD076676-01A1NICHD NIH HHS 2K24HD058735-06NICHD NIH HHS HHSN275201000003CNICHD NIH HHS HHSN275201000003INICHD NIH HHS K24 HD058735NICHD NIH HHS R01 HD076676NIGMS NIH HHS T32 GM086330NIGMS NIH HHS T32GM086330
6 · The paper itself

Abstract

backgroundTrimethoprim-sulfamethoxazole (TMP-SMX) is an antimicrobial drug combination commonly prescribed in children and adults. The study objectives were to validate and apply an HPLC-MS/MS method to quantify TMP-SMX in dried plasma spots (DPS) and dried urine spots (DUS), and perform a comparability analysis with liquid matrices.

resultsFor TMP the validated range was 100-50,000 ng/ml for DPS and 500-250,000 ng/ml for DUS; for SMX, the validated range was 1000-500,000 ng/ml for both DPS and DUS. Good agreement was noted between DPS/DUS and liquid plasma and urine samples for TMP, while only modest agreement was observed for SMX in both matrices.

conclusionA precise, accurate and reproducible method was developed to quantify TMP-SMX in DPS and DUS samples.

Indexed as

AdultCalibrationChildChromatography, High Pressure LiquidDried Blood Spot TestingHumansTandem Mass SpectrometryTime FactorsTrimethoprim, Sulfamethoxazole Drug CombinationUrinalysisTrimethoprim, Sulfamethoxazole Drug Combination

Identifiers

PMID26039810
PMCPMC4455038
OpenAlexW2174994428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.